Brief Title
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
Official Title
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.
Brief Summary
The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.
Study Type
Observational
Condition
Abscess, Intra-Abdominal
Intervention
CP-75385-02 Cefoperazone/sulbactam
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
0
Start Date
May 2007
Eligibility Criteria
Inclusion Criteria: - Male or female patient of age 18 years or older. - Patient with intraabdominal/hepatobiliary infection.? Exclusion Criteria: - Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Pfizer CT.gov Call Center, ,
Administrative Informations
NCT ID
NCT00463762
Organization ID
A1891004
Study Sponsor
Pfizer
Study Sponsor
Pfizer CT.gov Call Center, Study Director, Pfizer
Verification Date
April 2011